Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial

Afsoon Emami Naini, Mahnaz Moradi, Mojgan Mortazavi, Asghar Amini Harandi, Mehdi Hadizadeh, Farhad Shirani, Hamed Basir Ghafoori, Pardis Emami Naini, Afsoon Emami Naini, Mahnaz Moradi, Mojgan Mortazavi, Asghar Amini Harandi, Mehdi Hadizadeh, Farhad Shirani, Hamed Basir Ghafoori, Pardis Emami Naini

Abstract

In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease (ESRD) patients on hemodialysis received either L-carnitine 1 g/d (n = 24) or placebo (27 patients) for 16 weeks. At the end of the study, there was a significant decrease in triglyceride (-31.1 ± 38.7 mg/dL, P = 0.001) and a significant increase in HDL (3.7 ± 2.8 mg/dL, P < 0.001) levels in the carnitine group. Decrease in total cholesterol (-6.6 ± 16.0 mg/dL, P = 0.075) and increase in hemoglobin (0.7 ± 1.7 g/dL, P = 0.081) concentrations in the carnitine group were not significant. There was no statistically significant changes in LDL in any group (P > 0.05). Erythropoietin dose was significantly decreased in both the carnitine (-4750 ± 5772 mg, P = 0.001) and the placebo group (-2000 ± 4296 mg, P < 0.05). No improvement was observed in QOL scores of two groups. In ESRD patients under maintenance hemodialysis, oral L-carnitine supplementation may reduce triglyceride and cholesterol and increase HDL and hemoglobin and subsequently reduce needed erythropoietin dose without effect on QOL.

References

    1. Hosseinpanah F, Kasraei F, Nassiri AA, Azizi F. High prevalence of chronic kidney disease in Iran: a large population-based study. BMC Public Health. 2009;9(1, article 44)
    1. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition—need for strict control of risk factors. Internal Medicine. 2005;44(3):179–187.
    1. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. American Journal of Nephrology. 2008;28(6):958–973.
    1. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodialysis International. 2006;10(1):1–7.
    1. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and hemodialysis. American Journal of Kidney Diseases. 2003;41(3, supplement):S112–S126.
    1. Arduini A, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacology and Therapeutics. 2008;120(2):149–156.
    1. Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Nephrology. 2008;13(1):3–16.
    1. Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? American Journal of Kidney Diseases. 2005;46(3):371–386.
    1. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. Journal of the American Society of Nephrology. 2002;13(3):708–714.
    1. Saghaei M. Random allocation software for parallel group randomized trials. BMC Medical Research Methodology. 2004;4, article 26
    1. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Quality of Life Research. 2005;14(3):875–882.
    1. Tanzer F, Hizel S, Çetinkaya O, Sekreter E. Serum free carnitine and total triglycerid levels in children with iron deficiency anemia. International Journal for Vitamin and Nutrition Research. 2001;71(1):66–69.
    1. Karanth J, Jeevaratnam K. Effect of dietary lipid, carnitine and exercise on lipid profile in rat blood, liver and muscle. Indian Journal of Experimental Biology. 2009;47(9):748–753.
    1. Karanth J, Jeevaratnam K. Effect of carnitine supplementation on mitochondrial enzymes in liver and skeletal muscle of rat after dietary lipid manipulation and physical activity. Indian Journal of Experimental Biology. 2010;48(5):503–510.
    1. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney International. 1995;48(1):188–198.
    1. Shojaei M, Djalali M, Khatami M, Siassi F, Eshraghian M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iranian journal of kidney diseases. 2011;5(2):114–118.
    1. Semeniuk J, Shalansky KF, Taylor N, Jastrzebski J, Cameron EC. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Clinical Nephrology. 2000;54(6):470–477.
    1. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S. Results of a single blind, randomized, placebo-controlled clinical trial to study the effect of intravenous L-carnitine supplementation on health-related quality of life in Indian patients on maintenance hemodialysis. Indian Journal of Medical Sciences. 2006;60(4):143–153.
    1. Sloan RS, Kastan B, Rice SI, et al. Quality of life during and between hemodialysis treatments: role of L- carnitine supplementation. American Journal of Kidney Diseases. 1998;32(2):265–272.
    1. Savica V, Santoro D, Mazzaglia G, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. Journal of Renal Nutrition. 2005;15(2):225–230.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren